Liver disease and transplantation in telomere biology disorders: An international multicenter cohort
YunZu Michele Wang,Batul Kaj-Carbaidwala,Adam Lane,Suneet Agarwal,Fabian Beier,Alison Bertuch,Kristin A. Borovsky,Steven K. Brennan,Rodrigo T. Calado,Luiz Fernando B. Catto,Carlo Dufour,Christen L. Ebens,Francesca Fioredda,Neelam Giri,Nicholas Gloude,Frederick Goldman,Paula M. Hertel,Ryan Himes,Sioban B. Keel,Divya T. Koura,Christian P. Kratz,Sakil Kulkarni,Iris Liou,Taizo A. Nakano,Silvia Nastasio,Marena R. Niewisch,Daniel D. Penrice,Ghadir S. Sasa,Sharon A. Savage,Douglas A. Simonetto,David S. Ziegler,Alexander G. Miethke,Kasiani C. Myers,
DOI: https://doi.org/10.1097/hc9.0000000000000462
2024-06-19
Hepatology Communications
Abstract:Background: Patients with telomere biology disorders (TBD) develop hepatic disease, including hepatitis, cirrhosis, and hepatopulmonary syndrome. No specific treatment exists for TBD-related liver disease, and the role of liver transplantation (LT) remains controversial. Our study objectives were to describe the clinical characteristics, management, and outcomes in patients with TBD-related liver disease, and their LT outcomes. Methods: Data from 83 patients with TBD-associated liver disease were obtained from 17 participating centers in the Clinical Care Consortium of Telomere-Associated Ailments and by self-report for our retrospective, multicenter, international cohort study. Results: Group A (“Advanced”) included 40 patients with advanced liver disease. Of these, 20 underwent LT (Group A T ). Group M (“Mild”) included 43 patients not warranting LT evaluation, none of whom were felt to be medically unfit for liver transplantation. Supplemental oxygen requirement, pulmonary arteriovenous malformation, hepatopulmonary syndrome, and higher bilirubin and international normalized ratio values were associated with Group A. Other demographics, clinical manifestations, and laboratory findings were similar between groups. Six group A patients were declined for LT; 3 died on the waitlist. Median follow-up post-LT was 2.9 years (range 0.6–13.2 y). One-year survival post-LT was 73%. Median survival post-LT has not been reached. Group A T patients had improved survival by age compared to all nontransplant patients (log-rank test p = 0.02). Of 14 patients with pretransplant hypoxemia, 8 (57%) had improved oxygenation after transplant. Conclusions: LT recipients with TBD do not exhibit excessive posttransplant mortality, and LT improved respiratory status in 57%. A TBD diagnosis should not exclude LT consideration.
gastroenterology & hepatology